The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis

Journal of Human Hypertension

Volumn 16, Issue 6, 2002, Pages 391-397

  Erlinger, T P ^a,e   Conlin, P R ^b,e   Macko, R F ^b,e   Bohannon, A D ^c,e   Miller III, E R ^e   Moore, T J ^c,e   Svetkey, L P ^d,e   Appel, L J ^a,e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

African Americans; DASH; Fibrinolysis; Losartan; Tissue plasminogen activator (TPA)

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BIOCHEMICAL MARKER; LOSARTAN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN; SODIUM; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD PRESSURE REGULATION; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGRO; PLASMA RENIN ACTIVITY; PROTEIN ANALYSIS; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL;

ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIET, SODIUM-RESTRICTED; FEMALE; FIBRINOLYSIS; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0036088228     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001401     Document Type: Article

References (41)

1. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction
2. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group
3. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
4. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group
5. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators
6. Inhibition of platelet aggregability by losartan in essential hypertension
7. Angiotensin II AT(1) receptor antagonists and platelet activation
8. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study
9. Plaminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
10. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities
11. Haemostatic function and cardiovascular death: Early results of a prospective study
12. Haemostatic function and ischemic heart disease: Principle results of the Northwick Park Heart Study
13. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function
14. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans
15. Effect of activation and inhibition of the renin-angiotensin system of plasma PAI-1
16. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure
17. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension
18. Prospective study of endogenous tissue plasminogen activator and risk of stroke
19. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
20. Elevated tissue plasminogen activator antigen and stroke risk: The Stroke Prevention in Young Women Study
21. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension
22. A clinical trial of the effects of dietary patterns on blood pressure
23. Effect of dietary patterns on measures of lipid peroxidation: Results from a randomized clinical trial
24. Effect of dietary patterns on serum homocysteine: Results of a randomized, controlled feeding study
25. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects
26. Favorable long-term effect of a low-fat/high-fiber diet on human blood coagulation and fibrinolysis
27. Fasting blood coagulation and fibrinolysis of young adults unchanged by reduction in dietary fat content
28. Monounsaturated fatty acid-enriched diet decreases plasma plasminogen activator inhibitor type 1
29. Dietary regulation of fibrinolytic factors
30. The renin-angiotensin system and blood pressure: Differences between blacks and whites
31. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents
32. Rationale and design of the Dietary Approaches to Stop Hypertension trial (DASH): A multi-center controlled-feeding study of dietary patterns to lower blood pressure
33. An overview of methods for the analysis of longitudinal data
34. Clearance of tissue plasminogen activator (tPA) and tPA/plasminogen activator inhibitor type I (PAI-1) complex relationship to elevated tPA antigen in patients with high PAI-1 activity levels
35. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV
36. Hemostatic variables in Japanese and Caucasian men. Tissue plasminogen activator, antithrombin III, and protein C and their relations to coronary risk factors
37. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy
38. Prospective study of endogenous tissue plasminogen activator and risk of stroke
39. Plasma concentration of endogenous tissue plasminogen activator and the occurrence of future cardiovascular events
40. Coagulation and fibrinolysis factors in healthy subjects consuming high stearic or trans fatty acid diets
41. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris